search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


RESolutie van Ontsteking in de Luchtwegen na Virale Expositie.


- candidate number5342
- NTR NumberNTR1677
- ISRCTNISRCTN wordt niet meer aangevraagd
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR20-feb-2009
- Secondary IDs08/56 NAF 3-2-07-012
- Public TitleRESolutie van Ontsteking in de Luchtwegen na Virale Expositie.
- Scientific TitleThe role of indoleamine 2,3-dioxygenase in virus-induced asthma exacerbations.
- ACRONYMRESOLVE
- hypothesisWe hypothesize that allergic asthmatics are less capable in resolving inflammatory cells after viral airway infection as a consequences of impaired expression of indoleamine 2,3-dioxygenase.
- Healt Condition(s) or Problem(s) studiedAllergy, Asthma, Rhinovirus, Exacerbation
- Inclusion criteriaAllergic asthmatics:
1. Age between 18 and 40 yrs;
2. PC20 to methacholine below 8 mg/ml;
3. Skin-prick test positive to a least one common allergen.

Healthy:
1. Age between 18 and 40 yrs;
2. PC20 to methacholine above 16 mg/ml;
3. Skin-prick test negative to all common allergens.
- Exclusion criteriaAllergic asthmatics:
1. Current smokers;
2. Ex-smokers with more than 5 packyears;
3. Pre-FEV1 below 80% predicted;
4. Oral or inhaled steroid use;
5. Exacerbations during the past 6 weeks;
6. Underlying pulmonary condition other than asthma;
7. Non-pulmonary underlying conditions that may interfere with the study or that may result in unacceptable risk for the patient (incl. pregnancy);
8. Concomittant drug use (except short-acting bronchodilators);
9. Daily contact with young children (<2yrs).

Healthy:
1. Current smokers;
2. Ex-smokers with more than 5 packyears;
3. Pre-FEV1 below 80% predicted;
4. Oral or inhaled steroid use;
5. Underlying pulmonary condition other than asthma;
6. Non-pulmonary underlying conditions that may interfere with the study or that may result in unacceptable risk for the patient (incl. pregnancy);
7. Concomittant drug use (except short-acting bronchodilators);
8. Daily contact with young children (<2yrs).
- mec approval receivedyes
- multicenter trialno
- randomisedno
- groupParallel
- Type2 or more arms, non-randomized
- Studytypeintervention
- planned startdate 1-mrt-2009
- planned closingdate31-dec-2010
- Target number of participants42
- InterventionsHealthy volunteers and allergic asthma patients will be infected by rhinovirus-type 16 (10 TCID50) by spraying the virus into the nasal cavity, leading to mild common cold symptoms. In general, these symptoms will be more pronounced for allergic astmatics and will be scored daily by the volunteers (through a modified asthma control questionnaire (ACQ) and a common cold questionnaire (CCQ)). We expect that the increased symptoms scores in asthmatics is associated with enhanced inflammation of the airways. We will therefore include several inflammatory markers in our study. We used cytokine levels in bronchoalveolar lavage fluid to calculate the power of the study. In this study we are trying to correlate symptoms, inflammation, viral load and relevant biomarkers of IDO-mediated tryptophan degradation in blood and lavage fluid. We will also include non-invasive techniques to measure these end-points through NO measurements and exhaled breath condensate.
- Primary outcome1. Common cold questionnaire;
2. Asthma symptom score;
3. FEV1;
4. PC20 methacholine;
5. Inflammatory cell numbers;
6. Indoleamine 2,3-dioxygenase expression;
7. Apoptotic markers.
- Secondary outcome1. Exhaled NO;
2. ENose measurement;
3. Coagulation parameters.
- Timepoints1. 2 days prior to infection;
2. 4 days after infection (lung function testing only);
3. 6 days after infection.
- Trial web siteN/A
- statusstopped: trial finished
- CONTACT FOR PUBLIC QUERIESMD, PhD Peter J. Sterk
- CONTACT for SCIENTIFIC QUERIES K.F. Sluijs, van der
- Sponsor/Initiator Academic Medical Center (AMC), Department of Pulmonology
- Funding
(Source(s) of Monetary or Material Support)
Dutch Asthma Foundation (Nederlands Astma Fonds)
- PublicationsN/A
- Brief summaryTo investigate whether allergic asthmatics have an impaired capability to resolve inflammatory cells after viral airway infection, we will expose healthy individuals and allergic asthmatics to rhinovirus type 16. Volunteers will undergo two bronchoscopies to collect material before and after infection. In addition, lung function testing and asthma and common cold questionnaires will be included.
- Main changes (audit trail)
- RECORD20-feb-2009 - 18-okt-2012


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl